Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $13.13

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received an average rating of “Buy” from the nine research firms that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $13.13.

A number of brokerages have recently issued reports on CMPX. Guggenheim reduced their price objective on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a report on Friday, May 9th. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. HC Wainwright restated a “buy” rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Monday, April 28th. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st.

Insider Transactions at Compass Therapeutics

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Anderman purchased 20,000 shares of the company’s stock in a transaction dated Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the transaction, the insider now owns 21,000 shares of the company’s stock, valued at $32,340. This trade represents a 2,000.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 29.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after purchasing an additional 12,917 shares in the last quarter. Strs Ohio acquired a new stake in shares of Compass Therapeutics in the first quarter valued at approximately $34,000. Independent Advisor Alliance bought a new stake in Compass Therapeutics during the 4th quarter worth about $26,000. BNP Paribas Financial Markets bought a new stake in Compass Therapeutics during the fourth quarter worth about $27,000. Finally, Mariner LLC bought a new position in Compass Therapeutics in the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

NASDAQ:CMPX opened at $2.38 on Monday. The stock has a market cap of $329.11 million, a P/E ratio of -5.80 and a beta of 1.41. The company has a fifty day moving average price of $2.04 and a 200 day moving average price of $2.20. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). As a group, equities research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.